Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4348

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-4348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This text provides information about Fluticasone Propionate/Salmeterol Inhalation Diskus medication, which comes in a powder form with a strength of 500mcg/50mcg. The package contains 60 blisters and should be stored in a dry place away from direct heat or sunlight. It is for oral inhalation only and should be discarded one month after opening. The usual dosage instructions can be found in the insert. The medication is repackaged by RemedyRepack Inc. and manufactured by Prasco Laboratories. The lot number and NDC information are included for tracking purposes. It is important to keep this medication out of reach of children and store it within the specified temperature range.*

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

This description is not clear as it seems to be a list of medication names and dosages along with some numerical values related to pulmonary function tests. It is not possible to generate a useful description based on this text.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

This text provides information on a clinical study comparing different treatments for respiratory conditions based on the change in FEV4 (Forced Expiratory Volume in 4 seconds). The study includes groups receiving a combination of Fluticasone propionate/salmeterol, salmeterol alone, fluticasone propionate alone, and a placebo. The number of participants in each group is also provided, with the baseline measurement taken on Day 1.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

This is a comparison of the percentage change in Forced Expiratory Volume (FEV) relative to the baseline measurement taken on Day 1. The study involves different treatment groups including Fluticasone propionate/salmeterol, Salmeterol alone, Fluticasone propionate alone, and a Placebo group. The measurements were taken at different time points, from Day 1 to Week 12. The number of participants (N) in each treatment group is specified.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

This is a description of a clinical study comparing the efficacy of Fluticasone propionate/salmeterol DISKUS 250/50 mcg twice daily with Salmeterol 50 mcg twice daily and Placebo in patients with baseline FEV1 values. The study tracked measurements over a period of weeks and recorded the corresponding FEV1 values for each group. The data suggests that Fluticasone propionate/salmeterol DISKUS 250/50 mcg had a positive impact on the FEV1 values compared to the Salmeterol 50 mcg and Placebo groups.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

The text is not readable.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

This is a description for a medication called Putiasone with Salmeterol DISKUS inhalation powder. The device consists of a mouthpiece and a lever for administering the medication.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.